Since the expression levels of PD-L1 in tumor-derived exosomes are significantly associated with immune response and cancer progression, exosomal PD-L1 could be harnessed as a biomarker for contemplating cancer therapy responses (Figure 4). This evidence concerns the gene CD274 and cancer.